Andrew John Eatherton

Title: The Innovative Contributions of Andrew John Eatherton

Introduction

Andrew John Eatherton is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for cancer treatment. With a total of four patents to his name, Eatherton's work is recognized for its potential impact on medical science.

Latest Patents

Eatherton's latest patents include innovative compounds such as Imidazo[4,5-c]quinolin-2-one, which are aimed at treating cancer. The specifications of these patents generally relate to compounds of Formula (I). Another significant patent involves tetracyclic heteroaryl compounds, which also pertain to compounds of Formula (I) and their pharmaceutically acceptable salts. These patents detail processes and intermediates used for the preparation of these compounds, as well as pharmaceutical compositions containing them and their applications in treating cell proliferative disorders.

Career Highlights

Eatherton is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on developing innovative solutions for complex health challenges. His contributions have been instrumental in advancing research in the pharmaceutical industry.

Collaborations

Eatherton has collaborated with esteemed colleagues such as Bernard Barlaam and Kurt G. Pike. These collaborations have fostered a productive environment for innovation and have led to the development of groundbreaking pharmaceutical compounds.

Conclusion

Andrew John Eatherton's work exemplifies the spirit of innovation in the pharmaceutical field. His patents and collaborations highlight his commitment to advancing medical science and improving treatment options for patients.